News
VCYT
24.63
-1.91%
-0.48
Veracyte (VCYT) Securities Investigation Notice - Levi & Korsinsky
PR Newswire · 11h ago
Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo
Seeking Alpha · 11h ago
Veracyte Is Maintained at Overweight by Stephens & Co.
Dow Jones · 1d ago
Veracyte Price Target Cut to $40.00/Share From $55.00 by Stephens & Co.
Dow Jones · 1d ago
Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $40
Benzinga · 1d ago
Veracyte price target lowered to $40 from $55 at Stephens
TipRanks · 1d ago
Veracyte price target lowered to $40 from $66 at Freedom Capital
TipRanks · 2d ago
Veracyte Is Maintained at Overweight by Piper Sandler
Dow Jones · 2d ago
Veracyte Price Target Cut to $30.00/Share From $54.00 by Piper Sandler
Dow Jones · 2d ago
Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $30
Benzinga · 2d ago
Veracyte Price Target Cut to $40.00/Share From $66.00 by Freedom Capital Markets
Dow Jones · 2d ago
Veracyte Is Maintained at Buy by Freedom Capital Markets
Dow Jones · 2d ago
Freedom Capital Markets Maintains Buy on Veracyte, Lowers Price Target to $40
Benzinga · 2d ago
Veracyte (VCYT) Shareholder Investigation: Potential Securities Claims Reviewed Following Decipher Growth Outlook Reduction
TipRanks · 3d ago
Veracyte Price Target Cut to $35.00/Share From $65.00 by UBS
Dow Jones · 3d ago
Veracyte Is Maintained at Buy by UBS
Dow Jones · 3d ago
UBS Maintains Buy on Veracyte, Lowers Price Target to $35
Benzinga · 3d ago
VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law
Barchart · 3d ago
Analysts Offer Insights on Healthcare Companies: Astrana Health (ASTH) and Veracyte (VCYT)
TipRanks · 3d ago
Veracyte price target lowered to $35 from $65 at UBS
TipRanks · 3d ago
More
Webull provides a variety of real-time VCYT stock news. You can receive the latest news about Veracyte through multiple platforms. This information may help you make smarter investment decisions.
About VCYT
Veracyte, Inc. is a global diagnostics company. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder and TrueMRD for MIBC). It has developed the noninvasive Percepta Nasal Swab test to help physicians determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas. The Company has acquired the UroAmp platform, which has been clinically validated in non-muscle invasive bladder cancer (NMIBC), including therapy-response monitoring and post-treatment surveillance.